Celldex Therapeutics (NASDAQ:CLDX) Earns Buy Rating from HC Wainwright

Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They currently have a $80.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 92.08% from the company’s previous close.

Several other brokerages also recently issued reports on CLDX. Guggenheim raised their target price on shares of Celldex Therapeutics from $72.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. Cantor Fitzgerald reiterated an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a research note on Friday, March 22nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $66.00.

Celldex Therapeutics Price Performance

Shares of NASDAQ CLDX opened at $41.65 on Tuesday. Celldex Therapeutics has a fifty-two week low of $22.11 and a fifty-two week high of $53.18. The stock has a market capitalization of $2.33 billion, a price-to-earnings ratio of -14.31 and a beta of 1.60. The business has a 50-day moving average of $42.09 and a 200-day moving average of $36.87.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.19. Celldex Therapeutics had a negative net margin of 2,054.46% and a negative return on equity of 41.06%. The business had revenue of $4.13 million for the quarter, compared to the consensus estimate of $1.20 million. On average, sell-side analysts expect that Celldex Therapeutics will post -2.85 EPS for the current year.

Institutional Investors Weigh In On Celldex Therapeutics

Institutional investors have recently modified their holdings of the business. Jennison Associates LLC boosted its holdings in Celldex Therapeutics by 3,327.0% in the 1st quarter. Jennison Associates LLC now owns 688,080 shares of the biopharmaceutical company’s stock valued at $28,879,000 after purchasing an additional 668,002 shares during the period. Capstone Investment Advisors LLC boosted its stake in shares of Celldex Therapeutics by 50.7% in the first quarter. Capstone Investment Advisors LLC now owns 19,065 shares of the biopharmaceutical company’s stock valued at $800,000 after buying an additional 6,412 shares during the period. Principal Financial Group Inc. grew its position in Celldex Therapeutics by 10.0% during the first quarter. Principal Financial Group Inc. now owns 13,153 shares of the biopharmaceutical company’s stock worth $552,000 after buying an additional 1,194 shares in the last quarter. Assenagon Asset Management S.A. bought a new position in Celldex Therapeutics during the 1st quarter worth $3,816,000. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Celldex Therapeutics during the 1st quarter valued at $283,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.